NEFL and amyotrophic lateral sclerosis: In recent years, efforts to identify new reliable factors to be used for diagnosis and clinical trial design led to the discovery of new blood biomarkers, such as neurofilament light and phosphorylated heavy chains (NfL and pNfH, respectively), whose role in detection and risk stratification of ALS has been validated in several studies [2, 3].